The respiratory depressant effects of mitragynine are limited by its conversion to 7‐OH mitragynine

Mitragynine, the major alkaloid in Mitragyna speciosa (kratom), is a partial agonist at the μ opioid receptor. CYP3A‐dependent oxidation of mitragynine yields the metabolite 7‐OH mitragynine, a more efficacious μ receptor agonist. While both mitragynine and 7‐OH mitragynine can induce anti‐nociception in mice, recent evidence suggests that 7‐OH mitragynine formed as a metabolite is sufficient to explain the anti‐nociceptive effects of mitragynine. However, the ability of 7‐OH mitragynine to induce μ receptor‐dependent respiratory depression has not yet been studied.

[1]  Samuel T. Slocum,et al.  Oxidative Metabolism as a Modulator of Kratom's Biological Actions. , 2021, Journal of medicinal chemistry.

[2]  Stephen P. H. Alexander,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors , 2021, British journal of pharmacology.

[3]  Stephen P. H. Alexander,et al.  THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes , 2021, British journal of pharmacology.

[4]  C. Müller,et al.  Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats , 2021, Frontiers in Pharmacology.

[5]  G. Pasternak,et al.  Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom. , 2021, ACS chemical neuroscience.

[6]  Junmei Wang,et al.  Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined in Silico Pharmacokinetic and Pharmacodynamic Modeling Approach. , 2021, ACS chemical neuroscience.

[7]  Elyssa B. Margolis,et al.  A novel mitragynine analog with low efficacy mu-opioid receptor agonism displays antinociception with attenuated adverse effects , 2021, bioRxiv.

[8]  S. Sadhasivam,et al.  Pharmacogenomics of oxycodone: a narrative literature review. , 2021, Pharmacogenomics.

[9]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy , 2021, Clinical pharmacology and therapeutics.

[10]  J. Javitch,et al.  Site selective C–H functionalization of Mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy , 2020, Nature communications.

[11]  P. Law,et al.  Oxycodone in the Opioid Epidemic: High ‘Liking’, ‘Wanting’, and Abuse Liability , 2020, Cellular and Molecular Neurobiology.

[12]  H. Raja,et al.  Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions , 2020, Scientific Reports.

[13]  Astrid G. Stucke,et al.  Multi-Level Regulation of Opioid-Induced Respiratory Depression. , 2020, Physiology.

[14]  B. Avery,et al.  Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy. , 2020, ACS pharmacology & translational science.

[15]  Christopher H George,et al.  ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020 , 2020, British journal of pharmacology.

[16]  Ulrich Dirnagl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.

[17]  Justin O. Brower,et al.  Identification of five mitragyna alkaloids in blood and tissues using liquid chromatography-quadrupole/time-of-flight mass spectrometry , 2020, Forensic Toxicology.

[18]  E. Levitt,et al.  Kölliker-Fuse/Parabrachial complex mu opioid receptors contribute to fentanyl-induced apnea and respiratory rate depression , 2020, Respiratory Physiology & Neurobiology.

[19]  V. Rinne,et al.  Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions. , 2020, Biopharmaceutics & drug disposition.

[20]  Jack Durell,et al.  National Institute on Drug Abuse , 2020, Definitions.

[21]  G. Pasternak,et al.  G protein‐biased kratom‐alkaloids and synthetic carfentanil‐amide opioids as potential treatments for alcohol use disorder , 2019, British journal of pharmacology.

[22]  O. Grundmann,et al.  Current perspectives on the impact of Kratom use , 2019, Substance abuse and rehabilitation.

[23]  G. Pasternak,et al.  7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects , 2019, ACS central science.

[24]  Bin Zhou,et al.  Lateral Flow Assessment and Unanticipated Toxicity of Kratom. , 2018, Chemical research in toxicology.

[25]  S. Husbands,et al.  The novel μ‐opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception , 2018, British journal of pharmacology.

[26]  S. Nielsen,et al.  Identifying and treating codeine dependence: a systematic review , 2018, The Medical journal of Australia.

[27]  O. Grundmann.  Patterns of Kratom use and health impact in the US-Results from an online survey. , 2017, Drug and alcohol dependence.

[28]  G. Pasternak,et al.  Rubsicolins are naturally occurring G-protein-biased delta opioid receptor peptides , 2018, bioRxiv.

[29]  S. Narayanan,et al.  Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature , 2016, Brain Research Bulletin.

[30]  C. Müller,et al.  Neurobiology of Kratom and its main alkaloid mitragynine , 2016, Brain Research Bulletin.

[31]  J. Javitch,et al.  Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. , 2016, Journal of the American Chemical Society.

[32]  Lydia M. M. Vermeer,et al.  Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters , 2016, Drug Metabolism and Disposition.

[33]  H. Dringenberg,et al.  Abuse potential and adverse cognitive effects of mitragynine (kratom) , 2016, Addiction biology.

[34]  Sarah L. Withey,et al.  Ethanol Reversal of Tolerance to the Respiratory Depressant Effects of Morphine , 2015, Neuropsychopharmacology.

[35]  Z. Walsh,et al.  Experiences of Kratom Users: A Qualitative Analysis , 2015, Journal of psychoactive drugs.

[36]  Paul A Insel,et al.  Experimental design and analysis and their reporting: new guidance for publication in BJP , 2015, British journal of pharmacology.

[37]  E. Plise,et al.  Differential Effects of Rifampin and Ketoconazole on the Blood and Liver Concentration of Atorvastatin in Wild-Type and Cyp3a and Oatp1a/b Knockout Mice , 2014, Drug Metabolism and Disposition.

[38]  V. Navaratnam,et al.  Dose–Response Relationship, Acute Toxicity, and Therapeutic Index between the Alkaloid Extract of Mitragyna speciosa and Its Main Active Compound Mitragynine in Mice , 2013 .

[39]  S. Haertter.  Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6 , 2013, Drug metabolism and drug interactions.

[40]  J. Gudin.  Opioid therapies and cytochrome p450 interactions. , 2012, Journal of pain and symptom management.

[41]  Walter C. Prozialeck,et al.  Pharmacology of Kratom: An Emerging Botanical Agent With Stimulant, Analgesic and Opioid-Like Effects , 2012, The Journal of the American Osteopathic Association.

[42]  S. Fakurazi,et al.  Antinociceptive Action of Isolated Mitragynine from Mitragyna Speciosa through Activation of Opioid Receptor System , 2012, International journal of molecular sciences.

[43]  E. Boyer,et al.  Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity. , 2011, Current topics in medicinal chemistry.

[44]  S. Zoghbi,et al.  Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice. , 2010, Nuclear medicine and biology.

[45]  Howard S. Smith,et al.  Opioid metabolism. , 2009, Mayo Clinic proceedings.

[46]  J. Zadina,et al.  Reduced suppression of CO2-induced ventilatory stimulation by endomorphins relative to morphine , 2005, Brain Research.

[47]  H. Takayama.  Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. , 2004, Chemical & pharmaceutical bulletin.

[48]  H. Takayama,et al.  Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. , 2004, Life sciences.

[49]  S. Darke.  Polydrug use and overdose: overthrowing old myths. , 2003, Addiction.

[50]  D. Back,et al.  Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. , 1998, British journal of clinical pharmacology.

[51]  Shin-ichiro Sakai,et al.  Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors. , 1996, Life sciences.

[52]  J. Weisbach,et al.  Some observations on the pharmacology of mitragynine. , 1972, Archives internationales de pharmacodynamie et de therapie.